Official U.S. Pharmacopeia Wants to Import Marijuana
Published Date: 6/30/2026
Notice
Summary
The United States Pharmacopeial Convention wants to become an official importer of certain controlled substances like marijuana and its extracts. If you’re a registered manufacturer or interested party, you have until July 30, 2026, to share your thoughts or ask for a hearing. This move could impact how these substances are brought into the U.S., so keep an eye on the deadlines and get involved if it affects you!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Comment and Hearing Deadline
United States Pharmacopeial Convention applied on June 1, 2026 to be registered as an importer of Marihuana (drug code 7360) and Marihuana Extract (drug code 7350), both Schedule I. Registered bulk manufacturers and applicants may submit comments or requests for a hearing electronically or in writing on or before July 30, 2026.
Import for Analytical Reference Standards
The applicant seeks authorization to import Marihuana (7360) and Marihuana Extract (7350) for distribution as analytical reference standards to customers for analytical testing of raw materials. The application filed June 1, 2026 states no other activities for these drug codes are authorized under this registration.
Finished Dosage Forms Excluded
The notice expressly states that authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Entities seeking to import finished marijuana products for commercial sale would not be authorized under this registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19840, Christopher Nadorff, M.D.; Decision and Order
Dr. Christopher Nadorff from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19842, JT Medical, LLC; Decision and Order
JT Medical, LLC tried to get a DEA registration to handle marijuana but didn’t meet the rules because they couldn’t prove they had a real supply deal or a secure storage cabinet. Since they didn’t respond to the government’s concerns on time, their application was denied. This means JT Medical can’t legally handle marijuana products, and anyone working with them should look for other options.
2026-19839, Jorge J. Figueroa, M.D.; Decision and Order
Dr. Jorge J. Figueroa from New Jersey lost his DEA registration because he was kicked out of Medicare, Medicaid, and other federal health programs. He didn’t ask for a hearing, so the DEA made the decision official. This means he can’t legally handle controlled substances anymore, effective immediately, impacting his medical practice and income.
Previous / Next Documents
Previous: 2026-13163, Notification of Cancelled Adjustment of Civil Monetary Penalties for Inflation
Good news for 2026! The Federal Communications Commission is keeping civil penalty amounts the same—no inflation increases this year. If you deal with FCC rules, your fines won’t get bigger starting June 17, 2026, so no surprise hikes in your wallet.
Next: 2026-13165, Notice of Proposed Buy America Waiver for North County Transit District DMU Replacement Parts and Request for Comment
The North County Transit District asked for a special waiver to buy certain replacement parts for their 12 Siemens DMU trains that aren’t made enough in the U.S. The Federal Transit Administration is asking the public to share their thoughts before deciding. Comments are open until July 15, 2026, and this decision could affect how and where these parts are bought, possibly speeding up repairs and keeping trains running smoothly.